The ameliorating effect of Rutin on hepatotoxicity and inflammation induced by the daily administration of vortioxetine in rats

• Published in: BMC complementary and alternative medicine 2024-04, Vol.24 (1), p.153-153, Article 153
• Main Authors: Anwar, Mai M, Laila, Ibrahim M Ibrahim
• Format: Article
• Language: English
• Subjects: Acid phosphatase; Alanine; Alanine transaminase; Antidepressants; Antioxidants; Apoptosis; Aspartate; Aspartate aminotransferase; Biomarkers; Caspase-3; Depression, Mental; Design of experiments; DNA damage; DNA fragmentation; Drug dosages; Enzymatic activity; Enzymes; Ethylenediaminetetraacetic acid; Experimental design; Exposure; Galactosidase; Glucosaminidase; Glutathione; Glutathione transferase; Hepatitis; Hepatotoxicity; Inflammation; Injuries; Injury prevention; Kinases; L-Lactate dehydrogenase; Lactate dehydrogenase; Liver; Liver diseases; Liver injury; Mental depression; Oxidative stress; Phosphatases; Proteins; Rutin; Serotonin; Serotonin uptake inhibitors; SSRIs; Superoxide; Superoxide dismutase; Toxicity; Tumor necrosis factor-TNF; α-Fetoprotein; β-Galactosidase
• ISSN: 2662-7671; 2662-7671; 1472-6882
• DOI: 10.1186/s12906-024-04447-9

Vortioxetine (VORTX) is a potent and selective type of selective serotonin reuptake inhibitor (SSRI) that is mainly prescribed for treating major depression along with mood disorders as the first drug of choice. Limited previous findings have indicated evidence of liver injury and hepatotoxicity associated with daily VORTX treatment. Rutin (RUT), which is known for its antioxidant properties, has demonstrated several beneficial health actions, including hepatoprotection. Therefore the current study aimed to evaluate and assess the ameliorative effect of RUT against the hepatotoxic actions of daily low and high-dose VORTX administration. The experimental design included six groups of rats, each divided equally. Control, rats exposed to RUT (25 mg/kg), rats exposed to VORTX (28 mg/kg), rats exposed to VORTX (28 mg/kg) + RUT (25 mg/kg), rats exposed to VORTX (80 mg/kg), and rats exposed to VORTX (80 mg/kg) + RUT (25 mg/kg). After 30 days from the daily exposure period, assessments were conducted for serum liver enzyme activities, hepatotoxicity biomarkers, liver antioxidant endogenous enzymes, DNA fragmentation, and histopathological studies of liver tissue. Interestingly, the risk of liver damage and hepatotoxicity related to VORTX was attenuated by the daily co-administration of RUT. Significant improvements were observed among all detected liver functions, oxidative stress, and inflammatory biomarkers including aspartate aminotransferase (AST), alanine transaminase (ALT), lactate dehydrogenase (LDH), albumin, malondialdehyde (MDA), superoxide dismutase (SOD), glutathione (GSH), glutathione S-transferase (GST), total protein, acid phosphatase, N-Acetyl-/β-glucosaminidase (β-NAG), β-Galactosidase (β-Gal), alpha-fetoprotein (AFP), caspase 3, and cytochrom-C along with histopathological studies, compared to the control and sole RUT group. Thus, RUT can be considered a potential and effective complementary therapy in preventing hepatotoxicity and liver injury induced by the daily or prolonged administration of VORTX.